Related references
Note: Only part of the references are listed.Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy
E. R. Camp et al.
CANCER GENE THERAPY (2013)
Complement factor H-derived short consensus repeat 18-20 enhanced complement-dependent cytotoxicity of ofatumumab on chronic lymphocytic leukemia cells
Susanne Hoerl et al.
HAEMATOLOGICA (2013)
Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab
Srinivas Mamidi et al.
MOLECULAR ONCOLOGY (2013)
Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity
S. Hoerl et al.
LEUKEMIA (2013)
CD20 mAb-Mediated Complement Dependent Cytotoxicity of Tumor Cells is Enhanced by Blocking the Action of Factor I
Margaret A. Lindorfer et al.
ANTIBODIES (2013)
Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells
Christine Dufes et al.
THERAPEUTIC DELIVERY (2013)
Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
Weiguo Hu et al.
CANCER RESEARCH (2011)
rILYd4, a Human CD59 Inhibitor, Enhances Complement-Dependent Cytotoxicity of Ofatumumab against Rituximab-Resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia
Xiaowen Ge et al.
CLINICAL CANCER RESEARCH (2011)
Transferrin Receptor-Targeted Liposomes Encapsulating anti-BCR-ABL siRNA or asODN for Chronic Myeloid Leukemia Treatment
Liliana S. Mendonca et al.
BIOCONJUGATE CHEMISTRY (2010)
Inhibition of Membrane Complement Inhibitor Expression (CD46, CD55, CD59) by siRNA Sensitizes Tumor Cells to Complement Attack In Vitro
N. Geis et al.
CURRENT CANCER DRUG TARGETS (2010)
Complement: a key system for immune surveillance and homeostasis
Daniel Ricklin et al.
NATURE IMMUNOLOGY (2010)
Targeted delivery of doxorubicin using stealth liposomes modified with transferrin
XueMing Li et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2009)
Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development
Dana Gancz et al.
MOLECULAR IMMUNOLOGY (2009)
Targeting Hypoxia-inducible Factor-1α With Tf-PEI-shRNA Complex via Transferrin Receptor-mediated Endocytosis Inhibits Melanoma Growth
Yeqiang Liu et al.
MOLECULAR THERAPY (2009)
Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels
Myron S. Czuczman et al.
CLINICAL CANCER RESEARCH (2008)
Tf-lipoplexes for neuronal siRNA delivery: A promising system to mediate gene silencing in the CNS
A. L. C. Cardoso et al.
JOURNAL OF CONTROLLED RELEASE (2008)
Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack
S. Zell et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2007)
In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab
Paolo Macor et al.
CANCER RESEARCH (2007)
Cancer therapeutic antibodies come of age: Targeting minimal residual disease
Tsipi Ben-Kasus et al.
MOLECULAR ONCOLOGY (2007)
The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer
Tracy R. Daniels et al.
CLINICAL IMMUNOLOGY (2006)
Antitumoral activity of transferrin-lipoplexes carrying the IL-12 gene in the treatment of colon cancer
Conchita Tros De Ilarduya et al.
JOURNAL OF DRUG TARGETING (2006)
A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium
A. Santel et al.
GENE THERAPY (2006)
Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines
K Takei et al.
LEUKEMIA RESEARCH (2006)
Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo
AD Judge et al.
MOLECULAR THERAPY (2006)
Transferrin receptor-1 and 2 expression in chronic lymphocytic leukemia
T Smilevska et al.
LEUKEMIA RESEARCH (2006)
The in vitro antitumor effect and in vivo tumor-specificity distribution of human-mouse chimeric antibody against transferrin receptor
Ye Qing et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
被撤回的出版物: Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization (Retracted Article. See vol 24, pg 660, 2004)
MJ Tolentino et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2004)
The complement system in regulation of adaptive immunity
MC Carroll
NATURE IMMUNOLOGY (2004)
Future directions of liposome- and immunoliposome-based cancer therapeutics
JW Park et al.
SEMINARS IN ONCOLOGY (2004)
Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas
E Ryschich et al.
EUROPEAN JOURNAL OF CANCER (2004)
Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors
Z Fishelson et al.
MOLECULAR IMMUNOLOGY (2003)
Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells
F Czauderna et al.
NUCLEIC ACIDS RESEARCH (2003)
Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid
N Donin et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2003)
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59
J Golay et al.
BLOOD (2001)
K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement
K Jurianz et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Advances in immunology: Complement (First of two parts).
MJ Walport
NEW ENGLAND JOURNAL OF MEDICINE (2001)
CD55 is over-expressed in the tumour environment
L Li et al.
BRITISH JOURNAL OF CANCER (2001)
Expression of a complete and functional complement system by human neuronal cells in vitro
A Thomas et al.
INTERNATIONAL IMMUNOLOGY (2000)